Mohali: An unpaved, badly damaged stretch of road in Phase 7 turned into a major traffic hazard after three two-wheeler ...
Primary composite endpoint met: 61% of patients achieved visual and pathological response across all treated lesions.Complete clinical and pathological response in 56% of high-risk head & neck ...
The highest dose group of EP-104GI (Cohort 9) demonstrated durability of symptom responses out to 52 weeks, with 66% of ...
SHELTON, CT / ACCESS Newswire / September 29, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports ...
Eli Lilly (LLY) and Viking Therapeutics (VKTX) delivered back-to-back clinical wins in the same week — one pushing the ...
LNG Canada’s joint venture partners have taken a final investment decision on Phase 2, locking in a second pair of ...
Pharmacokinetic (PK) results reflected target-mediated drug disposition (TMDD) at low concentrations, confirming TX2100’s ...
cUHDRS showed 80% slowing of disease progression compared to the updated external control (nominal p=0.005). Treated patients ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a biopharmaceutical company dedicated to the discovery, development, manufacturing, ...
FDA Single IRB Rule for multisite trials advances to final rule status in December 2026, ending parallel IRB review for ...
Nice to meet you, I'm Miumi.I'm part of a family of five—my husband and our three children—and this year marks exactly 10 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results